MERAIODE: A Phase II Redifferentiation Trial with Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine-Refractory RAS-Mutated Differentiated Thyroid Cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MERAIODE: A Phase II Redifferentiation Trial with Trametinib and ¹³¹I in Metastatic Radioactive Iodine-Refractory RAS-Mutated Differentiated Thyroid Cancers

Published:2023-08-01 Issue:8 Volume:35 Page:336-338
ISSN:2329-9711
Container-title:Clinical Thyroidology®
language:en
Short-container-title:Clinical Thyroidology®

Author:

Pappa Theodora¹²

Affiliation:

1. Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, MA, U.S.A.

2. Head and Neck Oncology Cancer Treatment Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, U.S.A.

Publisher

Mary Ann Liebert Inc

Subject

General Engineering

Link

https://www.liebertpub.com/doi/pdf/10.1089/ct.2023%3B35.336-338

Reference6 articles.

1. Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

2. A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer

3. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and ¹³¹I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer

4. Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446).

5. Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP